Results 171 to 180 of about 1,993,809 (355)

A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 460-473, March 2025.
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Robin Michelet, Klas Petersson, Marc C. Huisman, C. Willemien Menke‐van der Houven van Oordt, Iris H. C. Miedema, Andrea Thiele, Ghazal Montaseri, Alejandro Pérez‐Pitarch, David Busse   +8 more
wiley   +1 more source

Response of the QT interval to mental and physical stress in types LQT1 and LQT2 of the long QT syndrome [PDF]

, 2001
Kristian Paavonen
openalex   +3 more sources

Dispersion of the QT Interval in Subjects with Frequent Nonsustained Ventricular Arrhythmias and No Underlying Heart Disease: Arrhythmogenic Substrate or Mechanoelectrical Feedback of Arrhythmias? [PDF]

, 2000
Gabriella Malfatto, Francesca Ciambellotti, Roberto Chianca, Renato Bragato, Giovanna Branzi, Gastone Leonetti, Mario Facchini   +6 more
openalex   +1 more source

Association Between QT-Interval Components and Sudden Cardiac Death: The ARIC Study (Atherosclerosis Risk in Communities)

Circulation: Arrhythmia and Electrophysiology, 2017
Wesley T. O’Neal, M. Singleton, Jason D. Roberts, L. Tereshchenko, N. Sotoodehnia, L. Chen, G. Marcus, E. Soliman   +7 more
semanticscholar   +1 more source

QT interval and SIDS. [PDF]

Circulation, 1983
openaire   +3 more sources

Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Given the high prevalence of the population who have metabolic dysfunction‐associated steatohepatitis (MASH), interest is growing in MASH‐targeted treatments. However, currently, there has been only one regulatory approved drug for MASH (Rezdiffra).
Quyen Thi Tran, Tham Thi Bui, Lien Thi Ngo, Bo Ram Yang, In‐Hwan Baek, Van Hung Nguyen, Kyung Ae Lee, Hwi‐yeol Yun, Jung‐woo Chae, Soyoung Lee, Jae Hyun Kim, Woojin Jung   +11 more
wiley   +1 more source

Long QT Interval Syndrome and Female Sex-Review and Case Report. [PDF]

Reports (MDPI)
Maričić L, Sušić L, Mihić D, Šego N.   +3 more
europepmc   +1 more source

Comparison of formulae for heart rate correction of QT interval in exercise ECGs from healthy children [PDF]

, 2001
Avram Benatar
openalex   +1 more source

A Case Study of Model‐Informed Drug Development of a Novel PCSK9 Antisense Oligonucleotide. Part 2: Phase 2 to Phase 3

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT In this second part of a case study on the practical use of model‐informed drug development (MIDD), we describe the clinical development of AZD8233, a novel proprotein convertase subtilisin/kexin type 9 (PCSK9) antisense oligonucleotide, from phase 2b to the start of phase 3.
Jane Knöchel, Catarina Nilsson, Björn Carlsson, Alexis Hofherr, Per Johanson, Tina Rydén‐Bergsten, Bengt Hamrén, Dinko Rekić   +7 more
wiley   +1 more source

QT Interval and Cardiac Restitution Ratio Complexity in Standardbred Racehorses From Rest to Maximal Effort: Insights Into Arrhythmia Risk. [PDF]

J Vet Intern Med
Avison A, Goderre BG, Pyle WG, Physick-Sheard PW.   +3 more
europepmc   +1 more source